Company news
Hinova Pharmaceuticals, Inc. Class A (SSE:688302) news
Hinova Pharmaceuticals, Inc. Class A news releases on 6ix. Latest, Sep 14, 2024: Announcement on Voluntary Disclosure of Obtaining FDA Approval for Clinical…
Press releases — page 2
Announcement on Voluntary Disclosure of Obtaining FDA Approval for Clinical Trial Application for HP515 Tablets to Treat Metabolic Dysfunction-Associated Steatohepatitis (MASH)
September 13, 2024
Announcement on Attending Semi-annual Collective Performance Briefing 2024 for Pharmaceutical and Biological Products Companies on STAR Market
September 6, 2024
Announcement on Voluntary Disclosure of Receiving the Notice of Approval for Clinical Trials of HP515 Tablets for the Treatment of Non-alcoholic Steatohepatitis (NASH)
August 27, 2024
Semi-annual Report in 2024
August 23, 2024
Announcement on Voluntary Disclosure of Receiving the Notice of Approval for Clinical Trials of HP560 Tablets for the Treatment of Myelofibrosis (Myeloproliferative Neoplasms)
July 24, 2024
Announcement on Voluntarily Disclosure of Obtaining FDA Approval for Phase I/II Clinical Trial Application of HP537 Tablets in the Treatment of Hematologic Malignancies
July 7, 2024